Xeroderma pigmentosum: Diagnostic procedures, interdisciplinary patient care, and novel therapeutic approaches;Xeroderma pigmentosum: Diagnostisches vorgehen, interdisziplinäre patientenversorgung und neue therapieansätze

JDDG - Journal of the German Society of Dermatology

Volumn 12, Issue 10, 2014, Pages 867-872

  Lehmann, Janin ^a   Schubert, Steffen ^a   Emmert, Steffen ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DNA REPAIR; EXCISION; EXCISION REPAIR; GENETICS; HUMAN; MOLECULAR DIAGNOSTICS; PATIENT CARE; PREVALENCE; SHORT SURVEY; TREATMENT INDICATION; XERODERMA PIGMENTOSUM; ADOLESCENT; ADULT; CHILD; COOPERATION; GENETIC COMPLEMENTATION; GENETIC PREDISPOSITION; INTERDISCIPLINARY COMMUNICATION; NEOPLASMS, RADIATION-INDUCED; NUCLEOTIDE SEQUENCE; PERSONALIZED MEDICINE; PROGNOSIS; SKIN NEOPLASMS; ULTRAVIOLET RADIATION; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; COOPERATIVE BEHAVIOR; DNA MUTATIONAL ANALYSIS; GENETIC COMPLEMENTATION TEST; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; INTERDISCIPLINARY COMMUNICATION; NEOPLASMS, RADIATION-INDUCED; PROGNOSIS; SKIN NEOPLASMS; ULTRAVIOLET RAYS; XERODERMA PIGMENTOSUM; YOUNG ADULT;

EID: 84907891589     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12419     Document Type: Short Survey

References (23)

1. Nouspikel T. DNA repair in mammalian cells: Nucleotide excision repair: variations on versatility. Cell Mol Life Sci 2009; 66(6): 994-1009.
2. Schubert S, Lehmann J, Kalfon L et al. Clinical utility gene card for: Xeroderma pigmentosum. 2014 Jul; 22(7).
3. Emmert S. Xeroderma pigmentosum, Cockayne Syndrome, and Trichothiodystrophy. In: Irvine A, Hoeger P, Yan A: Harper's Textbook of Pediatric Dermatology. Oxford: Wiley-Blackwell, 2011: 135.1-135.24.
4. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987; 123: 241-50.
5. Kashiyama K, Nakazawa Y, Pilz DT et al. Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia. Am J Hum Genet 2013; 92: 807-19.
6. Hirai Y, Kodama Y, Moriwaki S et al. Heterozygous individuals bearing a founder mutation in the XPA DNA repair gene comprise 1% of the Japanese population. Mutat Res 2006; 601: 171-8.
7. Tamura D, DiGiovanna JJ, Kraemer KH. Founder mutations in xeroderma pigmentosum. J Invest Dermatol 2010; 130: 1491-3.
8. Falik-Zaccai TC, Erel-Segal R, Horev L et al. A novel XPD mutation in a compound heterozygote; the mutation in the second allele is present in three homozygous patients with mild sun sensitivity. Environ Mol Mutagen 2012; 53(7): 505-14.
9. Takayama K, Salazar EP, Lehmann A et al. Defects in the DNA repair and transcription gene ERCC2 in the cancer-prone disorder xeroderma pigmentosum group D. Cancer Res 1995; 55(23): 5656-63.
10. Bradford PT, Goldstein AM, Tamura D et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterizes the role of DNA repair. J Med Genet 2011; 48: 168-76.
11. Kraemer KH, Slor H. Xeroderma Pigmentosum. Clin Dermatol 1985; 3: 33-69.
12. Lehmann AR. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev 2001; 15: 15-23.
13. Schäfer A, Gratchev A, Seebode C et al. Functional and molecular genetic analyses of 9 newly identified XPD-deficient patients reveal a novel mutation resulting in TTD as well as in XP/CS complex phenotypes. Exp Dermatol 2013; 22: 486-9.
14. Thoms K, Baesecke J, Emmert B et al. Functional DNA repair system analysis in hematopoietic progenitor cells using host cell reactivation. Scand J Clin Lab Invest 2007; 67: 580-8.
15. Schäfer A, Hofmann L, Gratchev A et al. Molecular genetic analysis of 16 XP-C patients from Germany: environmental factors predominately contribute to phenotype variations. Exp Dermatol 2013; 22(1): 24-9.
16. Khan SG, Oh KS, Shahlavi T et al. Reduced XPC mRNA levels in clinically normal parents of xeroderma pigmentosum patients. Carcinogenesis 2006; 27: 84-94.
17. Nagore E, Sevila A, Sanmartin O et al. Excellent response of basal cell carcinomas and pigmentary changes in xeroderma pigmentosum to imiquimod 5% cream. Br J Dermatol 2003; 149(4): 858-61.
18. Zahid S, Brownell I. Repairing DNA damage in xeroderma pigmentosum: T4N5 lotion and gene therapy. J Drugs Dermatol 2008; 7(4): 405-8.
19. Warrick E, Garcia M, Chagnoleau C et al. Preclinical corrective gene transfer in xeroderma pigmentosum human skin stem cells. Mol Ther 2012; 20(4): 798-807.
20. Kuschal C, DiGiovanna JJ, Khan SG et al. Repair of UV photolesions in xeroderma pigmentosum group C cells induced by translational readthrough of premature termination codons. Proc Natl Acad Sci 2013; 110(48): 19483-8.
21. Emmert S, Kraemer KH. Do not underestimate nucleotide excision repair: it predicts not only melanoma risk but also survival outcome. J Invest Dermatol 2013; 133(7): 713-7.
22. Kraemer KH, Sander M, Bohr VA. New areas of focus at workshop on human diseases involving DNA repair deficiency and premature aging. Mech Ageing Dev 2007; 128(2): 229-35.
23. Swift M, Chase C. Cancer in families with xeroderma pigmentosum. J Natl Cancer Inst 1979; 62: 1415-21.